Risk factors and Genetics
These ‘articles in a nutshell’ provide a balanced, straightforward and realistic overview of new science in Parkinson’s, and what it really means in the context of moving towards a cure.
It will take months or possibly years to definitively appreciate how the COVID-19 pandemic will affect people with
A new preclinical study has shown that LRRK2 inhibition in an animal model of Parkinson’s can improve lysosomal health and reduce alpha synuclein accumulation in dopaminergic neurons.
PINK1 may also protect cells and the brain from autoimmune attack
Using the largest ever genetics dataset
Discrepancies between end of life preferences
Parkinson’s is now held to be the fastest growing neurological disorder.
Recent studies show a link between the gut and Parkinson’s.
TMEM230 gene association with familial cases of Parkinson’s.
New research into the cellular clearance pathways governed by the GBA gene has shown reduced activity associated with both ageing and idiopathic Parkinson’s.
Largest UK population based study of PD found up to 10% of affected individuals carry a pathogenic mutation
New hypothesis which could reconceptualise Parkinson’s
Disease modifying efforts focusing on LRRK2
Common asthma drug may reduce Parkinson’s risk
Environmental factors could be connected to increase in Parkinson’s.
Falls and hip fractures may be indicative of Parkinson’s later in life.
Analysis of the PPMI dataset has shown that compared to people with sporadic forms of Parkinson’s, newly diagnosed people carrying GBA mutations are less severely impaired, and those with LRRK2 mutations appear more mildly affected.
Changes in smell, mood, and cognition in people with GBA1 mutations
Mediterranean diet seen to lower symptom risk
Study has found shared variants of LRRK2 gene.
Increased association found between hepatitis B and C and Parkinson’s.
Scientists uncovered how LRRK2 gene regulates cellular transport.
Pesticides inhibiting ALDH enzyme and increased Parkinson’s disease risk.